K V C Wevers-de Boer1, L Heimans1, K Visser1, J Kälvesten2, R J Goekoop3, M van Oosterhout4, J B Harbers5, C Bijkerk6, M Steup-Beekman7, M P D M de Buck8, P B J de Sonnaville9, T W J Huizinga1, C F Allaart1. 1. Department of Rheumatology, LUMC, Leiden, Zuid-holland, The Netherlands. 2. Sectra, Linköping, Sweden CMIV Linköping University, Linköping, Sweden. 3. Department of Rheumatology, Haga Hospital, The Hague, Zuid-holland, The Netherlands. 4. Department of Rheumatology, Groene Hart Hospital, Gouda, Zuid-holland, The Netherlands. 5. Department of Rheumatology, Franciscus Hospital, Roosendaal, The Netherlands. 6. Department of Rheumatology, Reinier de Graaf Gasthuis, Delft, The Netherlands. 7. Bronovo Hospital, The Hague, Zuid-holland, The Netherlands. 8. Department of Rheumatology, MCH, The Hague, Zuid-holland, The Netherlands. 9. Oosterschelde Hospital, Goes, The Netherlands.
Abstract
AIM: To assess whether in early (rheumatoid) arthritis (RA) patients, metacarpal bone mineral density (BMD) loss after 4 months predicts radiological progression after 1 year of antirheumatic treatment. METHODS:Metacarpal BMD was measured 4 monthly during the first year by digital X-ray radiogrammetry (DXR-BMD) in patients participating in the IMPROVED study, a clinical trial in 610 patients with recent onset RA (2010 criteria) or undifferentiated arthritis, treated according to a remission (disease activity score<1.6) steered strategy. With Sharp/van der Heijde progression ≥0.5 points after 1 year (yes/no) as dependent variable, univariate and multivariate logistic regression analyses were performed. RESULTS: Of 428 patients with DXR-BMD results and progression scores available, 28 (7%) had radiological progression after 1 year. Independent predictors for radiological progression were presence of baseline erosions (OR (95% CI) 6.5 (1.7 to 25)) and early DXR-BMD loss (OR (95% CI) 1.5 (1.1 to 2.0)). In 366 (86%) patients without baseline erosions, early DXR-BMD loss was the only independent predictor of progression (OR (95% CI) 2.0 (1.4 to 2.9)). CONCLUSIONS: In early RA patients, metacarpal BMD loss after 4 months of treatment is an independent predictor of radiological progression after 1 year. In patients without baseline erosions, early metacarpal BMD loss is the main predictor of radiological progression. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RCT Entities:
AIM: To assess whether in early (rheumatoid) arthritis (RA) patients, metacarpal bone mineral density (BMD) loss after 4 months predicts radiological progression after 1 year of antirheumatic treatment. METHODS: Metacarpal BMD was measured 4 monthly during the first year by digital X-ray radiogrammetry (DXR-BMD) in patients participating in the IMPROVED study, a clinical trial in 610 patients with recent onset RA (2010 criteria) or undifferentiated arthritis, treated according to a remission (disease activity score<1.6) steered strategy. With Sharp/van der Heijde progression ≥0.5 points after 1 year (yes/no) as dependent variable, univariate and multivariate logistic regression analyses were performed. RESULTS: Of 428 patients with DXR-BMD results and progression scores available, 28 (7%) had radiological progression after 1 year. Independent predictors for radiological progression were presence of baseline erosions (OR (95% CI) 6.5 (1.7 to 25)) and early DXR-BMD loss (OR (95% CI) 1.5 (1.1 to 2.0)). In 366 (86%) patients without baseline erosions, early DXR-BMD loss was the only independent predictor of progression (OR (95% CI) 2.0 (1.4 to 2.9)). CONCLUSIONS: In early RApatients, metacarpal BMD loss after 4 months of treatment is an independent predictor of radiological progression after 1 year. In patients without baseline erosions, early metacarpal BMD loss is the main predictor of radiological progression. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Bone Mineral Density; Early Rheumatoid Arthritis; Outcomes research
Authors: Alexander Pfeil; Anica Nussbaum; Diane M Renz; Christian Jung; Peter Oelzner; Ansgar Malich; Gunter Wolf; Joachim Böttcher Journal: Rheumatol Int Date: 2018-12-19 Impact factor: 2.631
Authors: L M Ørnbjerg; M Østergaard; T Jensen; K Hørslev-Petersen; K Stengaard-Pedersen; P Junker; T Ellingsen; P Ahlquist; H Lindegaard; A Linauskas; A Schlemmer; M Y Dam; I Hansen; T Lottenburger; C G Ammitzbøll; A Jørgensen; S B Krintel; J Raun; M L Hetland; Ole Slot; Lars Kjær Nielsen; Henrik Skjødt; Ole Majgaard; Tove Lorenzen; Hans Christian Horn; Marcin Kowalski; Inger Lauge Johansen; Peter Mosborg Pedersen; Natalia Manilo; Henning Bliddal Journal: Clin Rheumatol Date: 2016-12-05 Impact factor: 2.980
Authors: T Iwata; H Ito; M Furu; M Hashimoto; T Fujii; M Ishikawa; N Yamakawa; C Terao; M Azukizawa; Y Hamamoto; T Mimori; H Akiyama; S Matsuda Journal: Osteoporos Int Date: 2015-08-05 Impact factor: 4.507
Authors: Gülşah Akdemir; Marije K Verheul; Lotte Heimans; Kirsten V C Wevers-de Boer; Yvonne P M Goekoop-Ruiterman; Maikel van Oosterhout; Joop B Harbers; Casper Bijkerk; Gerda M Steup-Beekman; Leroy R Lard; Tom W J Huizinga; Leendert A Trouw; Cornelia F Allaart Journal: RMD Open Date: 2016-02-15
Authors: Alexander Pfeil; Peter Oelzner; Diane M Renz; Andreas Hansch; Gunter Wolf; Joachim Böttcher Journal: BMC Musculoskelet Disord Date: 2015-06-23 Impact factor: 2.362